Reliability of Longshi Scale With Remote Assessment
Reliability of Longshi Scale With Remote Assessment of Smartphone Video Calls for Stroke Patients'Activities of Daily Living
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China
- Shenzhen Second People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
a.Stroke survivors
- aged 18 and above;
- diagnosed with cerebral infraction or intracerebral hemorrhage;
- stroke onset2 weeks;
- stable vital signs (heart rate, blood pressure, respiratory rate, oxygen saturation and temperature);
voluntary or guardian consent to participate in the study.
b.Evaluators
- registered rehabilitation practitioner;
- experience in rehabilitation scientific research or education related work for more than two years
Exclusion Criteria:
a.Stroke survivors
- brain tumor, Parkinson's disease or active epilepsy within past three months;
- a history of mental illness such as mania or delirium;
- participation in any other clinical study. b.Evaluators
- unable to finish the training of Longshi Scale or use smartphones proficiently.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Assessed with the remote assessment of Longshi Scale first and then with bedside assessment
|
|
Assessed with the bedside assessment of Longshi Scale first and then with remote assessment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Consistency of the disability degree evaluated using the remote assessment and the bedside assessment of Longshi Scale.
Time Frame: Within 24 hours
|
Weighted kappa(wK) and Bland-Altman were used to determined the consistency between the results of remote assessment method and bedside assessment method.
The interpretation of wK scores was in accordance with published standards (values>0.75
indicating excellent agreement beyond chance; 0.4~0.75,
moderate agreement beyond chance; <0.4,
poor agreement beyond chance).
|
Within 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The test-retest reliability of the remote video assessment
Time Frame: Within 24 hours after first evaluation
|
the result of remote assessment test-retest was analyzed by Weighted kappa(wK) scores.The interpretation of wK scores was in accordance with published standards (values>0.75
indicating excellent agreement beyond chance; 0.4~0.75,
moderate agreement beyond chance; <0.4,
poor agreement beyond chance).
|
Within 24 hours after first evaluation
|
|
Satisfaction survey of remote assessment
Time Frame: Within 24 hours after the remote assessment
|
The satisfaction survey data were summarized as mean±standard deviation, and also summarized as the percentage of satisfaction categories.
|
Within 24 hours after the remote assessment
|
|
Assessment duration
Time Frame: Within 24 hours
|
The assessment duration was analyzed by independent t-test.
|
Within 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20220224002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.